Web Results


A doubling time < 6 months is considered a negative predictor, with prolonged treatment likely to be needed. PSA doubling time = ln (2) / PSA Slope; PSA Slope = (ln (PSA level 2) – ln (PSA level 1)) / Time (no. of months) The PSA velocity is the rate of PSA rise, expressed in nanograms/mL/year:


There is a certain amount of circular logic in statements about PSA doubling time (PSA-DT) and cancer progression. Most calculations of PSA-DT are derived from the last 3 PSA test results as recommended in the published literature. PSA progression is a commonly recognized surrogate measure of tumor progression.


The researchers looked at PSA doubling times of less than three months, three to nine months, nine to 15 months, and more than 15 months. The patients in the first two groups did poorly. The patients in the nine-to-15-month group did fairly well. [See “PSA doubling time,” below.]


PSA doubling time: BMI: Ideal Body Weight: Weight Conversion: IV Infusion rate : IV Drip rate : Drug Dosage Calculator : links to other sites : ... Cardiovascular risk Calculator (University of Edinburgh) eGFR Calculator (The Renal Association) Kattan's Nomograms - For Prostate Cancer (Memorial Sloane Kettering, ...


The doubling time is the amount of time that it takes for a quantity of something to double in size. Doubling time is more commonly known as the rule of 70. This formula is most helpful for populations or quantities that are experiencing exponential growth.


The PSA doubling time, from the first post biopsy PSA score in Feb 2018 to the last one in March 2019, taking all the intervening scores into account, is in negative figures, (-) 6.7yrs with a velocity of (-) 1.3ng/ml/yr.


Online calculator for lung nodule volume-doubling time, copyright: Tore Sjøboden


PSA doubling time (PSADT) among patients with castration-resistant prostate cancer (CRPC) strongly predicts their risk for metastatic disease and all-cause and cancer-specific mortality, according ...


level. We use doubling rule of PSA for these patient at the decision making of the biopsy to prostate cancer. But the guidelines of BPH and prostate cancer do not mention when we can use the doubling rule for BPH patients in many countries. Several guidelines provide the information that PSA level reaches to about 50% after 6 months of treatment.


In Canada, Dr. Klotz studied PSADT in a group of men diagnosed with early, localized disease. The median PSADT in the cohort was 7 years. about 22% had a doubling time of less than 3 years, and 42% had a doubling time of more than 10 years. Rapid PSA progression has generally been defined as a doubling time of less than 3 years.